Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618786 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL4662240 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL764578 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL6525814 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL19578680 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL6525816 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL8303249 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL22242735 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL21238714 | 1.00 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| Ammonia Solution, Strong SCHEMBL6519837 | 0.98 | BTK (0.50) | BTKGAAEPHX1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | NOVOSTAR PHARMACEUTICALS, LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2011104334-A1 | 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| US-20110053902-A1 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-03-03 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | BTK 4552/4885GAA 592/4885EPHX1 675/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | BTK 3624/4885GAA 1395/4885EPHX1 1748/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | BTK 2629/4885GAA 4432/4885EPHX1 4180/4885 |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | BTK 101/4885GAA 1357/4885EPHX1 2803/4885 |
| US-20110053902-A1 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | PKD1, ATP1A2, ATP1A1 | BTK 3637/4885GAA 1920/4885EPHX1 1259/4885 |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | BTK 695/4885GAA 1503/4885EPHX1 1769/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | BTK 2055/4885GAA 309/4885EPHX1 363/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | BTK 710/4885GAA 983/4885EPHX1 2522/4885 |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | PARP1, PARP3, PARP11 | BTK 2788/4885GAA 1143/4885EPHX1 2791/4885 |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | CLIC1, HCCS, CNR1 | BTK 844/4885GAA 2477/4885EPHX1 1782/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | BTK 3624/4885GAA 1395/4885EPHX1 1748/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | BTK 3624/4885GAA 1395/4885EPHX1 1748/4885 |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | CBR1, CLIC1, RER1 | BTK 562/4885GAA 2303/4885EPHX1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.